Home>>Signaling Pathways>> Cell Cycle/Checkpoint>> Microtubule/Tubulin>>McMMAF (Maleimidocaproyl monomethylauristatin F)
McMMAF (Maleimidocaproyl monomethylauristatin F) Catalog No.GC34068

Size Price Stock Qty
10mM*1mLinDMSO
$1,403.00
In stock
1mg
$506.00
In stock
5mg
$901.00
In stock
10mg
$1,379.00
In stock

Customer Review

Based on customer reviews.

Tel: (626) 353-8530 Email: sales@glpbio.com

Sample solution is provided at 25 µL, 10mM.

Chemical Properties

Cas No. 863971-19-1 SDF Download SDF
Synonyms N/A
Chemical Name N/A
Canonical SMILES O=C([C@H](C)[C@H]([C@]1([H])CCCN1C(C[C@@H](OC)[C@@]([H])(N(C([C@H](C(C)C)NC([C@H](C(C)C)N(C)C(CCCCCN2C(C=CC2=O)=O)=O)=O)=O)C)[C@@H](C)CC)=O)OC)N[C@H](C(O)=O)CC3=CC=CC=C3
Formula C49H76N6O11 M.Wt 925.16
Solubility DMSO : ≥ 100 mg/mL (108.09 mM) Storage Store at -20°C
General tips For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months.
Shipping Condition Evaluation sample solution : ship with blue ice
All other available size: ship with RT , or blue ice upon request
  • Molarity Calculator

  • Dilution Calculator

Mass
=
Concentration
x
Volume
x
MW*
 
 
 
**When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / CoA (available online).

Calculate

Background

Mc-MMAF is a protective group-conjugated MMAF. MMAF is a more potent drug than Monomethyl auristatin E (MMAE), but is charged and relatively membrane-impermeable, is a potent tubulin inhibitor, is a toxin payload in antibody drug conjugate.Target:MMAF is a new auristatin derivative with a charged C-terminal phenylalanine that attenuates its cytotoxic activity compared to its uncharged counterpart, Monomethyl auristatin E (MMAE). Because of MMAF is highly toxic, it cannot be used as a drug itself. MMAF induces potent antitumor effects when conjugated via protease cleavable linkers to a monoclonal antibody targeting internalizing, tumor-specific cell surface antigens. The linker to the monoclonal antibody is stable in extracellular fluid, but is cleaved by cathepsin once the conjugate has entered a tumor cell, thus activating the anti-mitotic mechanism.

[1]. Polson AG, et al. Antibody-drug conjugates for the treatment of non-Hodgkin’s lymphoma: target and linker-drug selection. Cancer Res. 2009 Mar 15;69(6):2358-2364. [2]. Jianmin Fang, et al. Anti-her2 antibody and conjugate thereof. US 20160304621 A1.